Suven Life Sciences, Drug firm has been granted 2 product patents, one each in India and Japan, for molecules to be developed for treating neuro-degenerative diseases. As per the company’s filling, the company has been given one product patent from India and one from Japan corresponding to the new chemical entities (NCEs) for treating disorders related with neuro-degenerative diseases. These patents will be valid through 2026 and 2032, respectively, it further added. The products will be used in the treatment of cognitive impairment related with neuro-degenerative disorders namely- Huntington's disease, Alzheimer's disease, attention-deficient hyperactivity disorder, major depressive disorder, Parkinson's and schizophrenia.
Venkat Jasti, Suven Life Sciences CEO said that they are very satisfied by the grant of these patents to Suven for their pipeline of molecules in CNS (central nervous system) arena that are have been developed for cognitive disorders with high unmet medical need with great market potential worldwide. With these new patents, Suven has an aggregate of 19 granted patents from India and 19 from Japan, the company mentioned. Also, products out of these inventions can be out-licensed at various phases of clinical development like in phase-I or phase-II.
Suven share price settled below 1% at Rs. 189.60. The stock quoted at Rs. 190.50, touching the day’s high and low at Rs. 195.75 and Rs. 188.10, respectively. Throughout the entire day around 6,95,885 shares were traded in the counter with a traded value of Rs. 1,332.83 lacs.
Suven is analyzed by Dynamic Levels as the top 500 performing stocks for the June quarter among the 1700 stocks which are listed on the NSE. Suven is fundamentally strong and is safe for investment, as per Dynamic analysts.
In order to acquire more details on the support and resistance levels and also the fundamentals and financials of the stock, kindly refer to Suven share price forecast.
No comments:
Post a Comment